News

News

New modified antibiotic may prove effective against >200 resistant pathogens

To create a novel molecule that may be effective against resistant Gram-negative bacteria, researchers at University…

New WHO pipeline report on bacterial vaccines issued

Vaccines are powerful tools to prevent infections in the first place that could later on lead…

Biomérieux, Evotec and Boehringer Ingelheim team up in new €40m joint venture

The companies Biomériux, Evotec and Boehringer Ingelheim have joined forces against AMR and announced the launch…

Commonwealth leaders discuss AMR

Commonwealth leaders have convened in Kigali, Rwanda, to discuss the challenge of antimicrobial resistance and the…

New report issued by Global AMR R&D Hub and WHO

Increasing cases of antibiotic resistance endanger global health and the availability of modern healthcare. Till date,…

CARB-X receives additional US$ 370m from US Government and Wellcome Trust

CARB-X (part of Boston University) announces the renewal of its support from Wellcome Trust, a worldwide…

Vivli awarded contract by Wellcome Trust to improve use of AMR surveillance data

The availability of surveillance data on antimicrobial resistance (AMR) makes it possible to assess incidence rates…

COVID-19 pandemic may be accelerating antimicrobial resistance: new US study published

A new study by BD (Becton Dickinson) and MSD (Merck & Co.) found higher rates of…

UK to launch world-first subscription model for antibiotics

With the goal of counteracting the growing world-wide crisis over resistance to antibiotics, the United Kingdom…

The case for a subscription model to tackle AMR: new BCG report published

The recently published report by Boston Consulting Group, prepared together with World Economic Forum, Wellcome Trust,…

New report issued by Milken Institute and Wellcome Trust on financing antibiotic development

FasterCures and Financial Innovations Labs® have joint forces on a project to identify new financing models to…

ArrePath receives $20 million seed financing to advance its machine learning-based platform for novel anti-infectives

ArrePath announced that it has raised $20 million in seed financing to advance its proprietary, machine…

New report issued by BIO on the state of the R&D pipeline

BIO has published a new report that takes a closer look at the recent investment into…

Bugworks Research secures $18M Series B1 funding from reputed Global Investor Syndicate

BWC0977, Bugwork’s candidate for a novel broad spectrum anti-bacterial agent, will be further developed with financial…

AMR Action Fund opens European office in Basel

The AMR Action Fund has moved into its new European office in Basel. The venture fund…

AMR Action Fund appoints nine new SAB members

The AMR Action Fund has named several experts as members of its Scientific Advisory Board (SAB).…

French biotech Mutabilis announces collaboration with Roche

Mutabilis, based in Romainville, France, announced that it has closed the deal on a Research Collaboration…

Five pillars for effective AMR pull incentives in Europe

BEAM Alliance has released a new position paper outlining five pillars for an effective AMR pull…

AI system AlphaFold added WHO priority pathogens to its library

By using its AI-based system AlphaFold British company DeepMind has added the predicted proteome of almost…

First innovators selected by INCATE

A total of four ventures, three from Germany and one from Finland, have been selected by…

AMR among priorities for German G7 Presidency

The German government has released its policy priorities for the G7 Presidency in 2022 and confirmed…

Two new requests for proposals released by BARDA and NIAID

Just recently, NIAID and BARDA both have published requests for proposals for the areas of therapeutics…

Study on global AMR burden published in The Lancet

At least 1.27 million deaths per year are directly attributable to AMR, says a new study…

New €19m JPIAMR call now open

Within the framework of the ERA-NET JPIAMR-ACTION, JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) is launching…

A faster way to diagnose antibiotic resistance utilizing AI

As of recently, collaborative research between ETH Zürich, University Hospital Basel, and the University of Basel…

Early-stage ventures fighting AMR wanted!

Don’t miss to participate in the start-up competition @AMR conference supported by INCATE. Early-stage ventures fighting drug…

New pipeline report by WHO

The WHO has released a new report analyzing the current antibacterial pipeline. It has been published…

Employing supercomputers to fight antibiotic resistance

Approximately 700,000 people are estimated to die due to infection by antibiotic-resistant bacteria every year, with…

€9m funding for the multidisciplinary consortium ARPEGE

By combining preventive, diagnostic, therapeutic and economic approaches for the first time the ARPEGE consortium led…

Podcast episode on phage therapy with Dr. Richard Alm at CARB-X

CARB-X Chief Scientist Dr. Richard Alm joins host Steven Yang for this episode of The Phage…

Fighting AMR through rapid digital pandemic response

In December, a consortium of 8 public and 4 private Swiss institutions has joined forces to…

Interview with Rusudan Okujava, Roche

Pharma company Roche is among the partners of AMR-focused incubator INCATE. We spoke with Rusudan Okujava…

CARB-X surpasses all goals in first five years

With US$361 million awarded to 92 projects funding, CARB-X closed the fifth fiscal year since inception.…

FIND invests US$21m into molecular testing companies

In late December, FIND announced an investment of US$21 million to accelerate the development, manufacturing, and…

Ares Genetics to expand ARESdb proprietary contents

Diagnostics company Ares Genetics GmbH, developing NGS- and AI-powered solutions to combat AMR, has successfully completed…

G7 released new statement to support antibiotic development

The G7 Finance Ministers have released a statement on actions to support antibiotic development, with the goal…

BioNTFAO releases new 5-year Action Plan to combat AMR

The UN Food and Agriculture Organization BioNTFAO has issued an Action Plan spanning a total of…

The innovative life of SMEs

On the occasion of the World Antibiotic Awareness Week (WAAW), BEAM Alliance has published a series…

Interview with: Marc Gitzinger, BEAM Alliance & BioVersys

BEAM Alliance is among the partners of AMR-focused incubator INCATE. We spoke with Marc Gitzinger, CEO…

New report of animal health R&D funding patterns

Together with the International Development Research Center (IDRC), the Global AMR R&D Hub published a new…

Interview with: Philipp Müller, Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund is among the industry partners of AMR-focused incubator INCATE. We spoke…

Interview with: Hideki Maki, Shionogi

The Japanese pharma company Shionogi is among the industry partners of AMR-focused incubator INCATE. We spoke…

BioNTech acquires Vienna-based start-up PhagoMed

BioNTech SE has acquired PhagoMed GmbH, an Austrian start-up for precision antimicrobial treatments supported by the…

PASTEUR Act re-introduced in US Senate

In mid-November, the AMR community welcomed the official introduction of Cures 2.0 by the bipartisan team of U.S.…

New €9m vaccine project to combat AMR with big data and AI

A new European consortia called PrIMAVeRA is developing an open-source, web-based platform combining mathematical models with…

Antibiotic Research UK to fund seven new research projects worth £200,000 in total

Antibiotic Research UK (ANTRUK) announced that through its 2021 Small Research Grants / Career Development Awards…

Analysis is estimating the appropriate size of global pull incentives

A new analysis published by Kevin Outterson in the Health Affairs journal is estimating the appropriate…

Session report: COVID-19 impact and lessons learned

AMR experts from Industry, SMEs, academia and public bodies discussed the impact of COVID-19 on AMR…

Session report: Updates on funds & accelerators

Investment climate for companies active in AMR was rather weak for a long time. However, over…

Session report: How to go ahead with pull incentives?

During the third day of the virtual 5th AMR Conference, the important role of governments and…

Pharma-backed start-up incubator launched

With INCATE a new public-private consortium was launched on 25 August to boost the development of…

How investors evaluate the AMR sector?

We spoke with Aleks Engel from the Novo Holdings Repair Impact Fund, one of the speakers…

Limited patient access to new antibacterials in high-income countries

A group of experts has shown in an analysis that also in high-income countries patient access…

Global AMR R&D Hub with new report

The Global AMR R&D Hub has published a report which highlights the mismatch between global needs…

CARB-X celebrates success in Europe

CARB-X is organizing a webinar to celebrate its European projects and funding partners which have supported…

Survey on AMR Multi-stakeholder Partnership Platform started

The Tripartite organizations (FAO, OIE, WHO) are conducting a public discussion survey on the development of…

£19.2 million for cross-government AMR surveillance project in UK

The British cross-departmental project team behind Pathogen Surveillance in Agriculture, Food and the Environment (PATH-SAFE) brings…

What antibiotics developers can learn from COVID-19 vaccine trials

British clinical trials expert Stephen Senn explains in a viewpoint essay on the GARDP website what…

The Global Fund grants US$37 million to FIND to advance tuberculosis prevention and control in India

FIND, the global alliance for diagnostics, and the Global Fund announced that FIND has been awarded…

New AMR research alliance tackling animal and human health

A new London-Liverpool research alliance in UK will bring together academic and commercial sectors in a…

New study finds variations in antibiotic consumption across Europe between 2014 and 2018

The European Centre for Disease Prevention and Control (ECDC) together with WHO Regional Office for Europe…

EU policymakers urged to consider AMR incentive models

In an EURACTIV report, policymakers across the EU are being urged to consider the full range…

Newly published guidance enables advances in testing for TB and drug resistance

FIND has contributed to two major documents recently published by the WHO that represent major advances…

New $60m mRNA vaccines programme by Wellcome Trust and CEPI

CEPI and Wellcome Trust have joined forces to further exploit the mRNA technology. To prepare for…

New collaboration between ICARS and the Global AMR R&D Hub

The Global AMR R&D Hub and ICARS announced a new partnership that will further strengthen their…

UNITE4TB launched under the umbrella of the IMI AMR Accelerator

A 7-year, €185 million project called UNITE4TB was started by 30 partners from 13 countries as…

JPIAMR’s Virtual Research Institute expands its digital platform to connect datasets

The JPIAMR’s Virtual Research Institute (JPIAMR-VRI) recently updated its digital platform to a large extent, now…

LSHTM partners with Johnson & Johnson

The London School of Hygiene & Tropical Medicine (LSHTM) has entered into a new partnership with…

Acurx Pharmaceuticals announces closing of initial public offering of common stock

Acurx Pharmaceuticals Incorporated, a clinical stage biopharmaceutical company committed to the development of a novel class…

Destiny Pharma and US Department of Veterans Affairs team up to fight Clostridioides difficile infections

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company for the development of novel…

AMR Preparedness Index shows UK and US among best prepared

The Global Coalition on Aging (GCOA) together with the Infectious Diseases Society of America (IDSA) have…

Horizon Europe launches two new AMR-focused calls

The EU’s Research and Innovation funding programme, Horizon Europe, has launched its research calls for 2021-2022…

GW4 AMR Alliance to become the UK’s leading ‘One Health’ AMR research consortium

AMR is a complex, multi-faceted problem that affects all of society and is driven by many…

US Senate re-introduces PASTEUR Act

The US Senate has reintroduced the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act…

New BARDA Ventures will invest $500m to prepare for future health challenges

BARDA have announced the creation of a new venture to develop and commercialize technologies and medical…

EPSRC funds new programme ‘Beyond Antibiotics’

The 5-year programme will start in October 2021. Scientists from the Universities of Oxford, Ulster and…

Nanotherapeutics Hub joins forces with iiCON

The Nanotherapeutics hub and iiCON step up the UK’s infectious disease R&D pipeline. iiCON, led by…

Second financing for BioVersys from CARB-X

CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in…

GARDP and DNDi publish policy brief at 74th WHA

GARDP together with DNDi published a policy briefing statement at the 74th World Health Assembly. According…

Basilea supported by CARB-X funding

CARB-X is awarding Swiss listed company Basilea Pharmaceutica International up to US $2.7m to develop a novel class…

Sandoz is investing €150m in its antibiotics manufacturing setup in Europe

Sandoz, a Novartis division, has announced plans to invest €150m and further strengthen its European antibiotics…

CARB-X backs Summit Therapeutics with up to $4.1m

Up to $4.1 million in non-dilutive funding are being awarded by CARB-X to UK-based Summit Therapeutics. The capital…

BARDA seeks proposals for new Antibacterial Accelerator

BARDA is seeking proposals for a new Antibacterial Accelerator which is funded for the next ten…

High-level Interactive Dialogue on AMR

End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a…

Pfizer grows infectious disease pipeline

US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal…

Diagnostics company GenomeKey funded by CARB-X

CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive…

X-Biotix stops antibacterial activities

US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial…

Bacteriophage-company Pico Therapeutics backed by CARB-X

CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug…

Update on WHO pipeline report available

The WHO has published their updated analysis for the clinical and preclinical antibacterial product pipeline in…

BioVersys gets €20m EIB loan to develop novel antibiotics

Swiss BioVersys has received €20m from the European Investment Bank to push the development of new…

EU starts consultation process on HERA

The European Commission launched an online public consultation on the Health Emergency Preparedness and Response Authority…

University of Oxford receives funding

CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of…

Guidance on Stewardship and Access for developers published

Led by Wellcome Trust, a group of AMR funders has published the first guidance on strategies…

New study on national policy options

The Global AMR R&D Hub has published a study on national policy options to reward the…

GSK receives up to $18m CARB-X funding for two vaccine projects

CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH),…

French biotech Mutabilis funded by CARB-X

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to…

CARB-X will invest up to US$15m for German AMR projects

CARB-X announced the investment of first grants to two German research teams from the German Helmholtz…

CARB-X is funding a team of top German researchers to develop a drug to treat Staphylococcus aureus infections and prevent exacerbation of life-threatening pneumonia

Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC)…

CARB-X is funding a German team of scientists to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all…

Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium

Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and…